// App-Quantinova.ai

: Randomized trial of five or two MRI-guided adaptive radiotherapy treatments for prostate cancer (FORT).

Researchers

Presenter

  • Ariel E. E. Marciscano

Principal Investigators

  • Xi K. Zhou

  • Sydney Wolfe

  • Amar Upadhyaya Kishan

  • Michael L. Steinberg

  • Philip Camilleri

  • Jones T. Nauseef

  • Ana M. Molina

  • Cora N. Sternberg

  • David M. Nanus

  • Scott T. Tagawa

  • Daniel Margolis

  • Joseph Osborne

  • Timothy D McClure

  • Jim C. Hu

  • Douglas Scherr

  • Christopher Barbieri

  • Himanshu Nagar

Medical Centers

  • Weill Cornell Medicine, Hematology/Oncology, Englander Institute for Precision Medicine, Meyer Cancer Center, New York, NY

  • Weill Cornell Medical College of Cornell University, New York, NY

  • Weill Cornell Medicine, New York, NY

  • New York-Presbyterian Hospital/Weill Cornell Medicine, New York, NY

  • Olive View-UCLA Medical Center, Los Angeles, CA

  • Weill Cornell New York Presbyterian, New York, NY

  • University of California, Los Angeles, Los Angeles, CA

  • New York Genome Center, New York, NY

  • University of Oxford Medical Oncology Department, Oxford, United Kingdom

Locations

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Prostate cancer

Biomarkers

  • Folate Hydrolase 1

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Randomized

  • Adaptive

  • Non Inferiority

Phase

  • II

Study Id's

  • NCT04984343

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved